| stable angina | versus placebo or control No demonstrated result for efficacy | 6 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Gupta et al, 1997 | Azithromycin vs placebo | | | all cause death 0.50 [0.03; 7.59] Acute coronary syndrome (MI ou unstable angina) 0.64 [0.19; 2.09] | | ACADEMIC, 1999 | Azithromycin vs placebo | | | all cause death 1.25 [0.34; 4.56] Myocardial infarction (fatal & non fatal) 0.68 [0.19; 2.35] Acute coronary syndrome (MI ou unstable angina) 0.94 [0.44; 1.98] | | WIZARD, 2003 | Azithromycin vs placebo | | | all cause death 0.93 [0.76; 1.14] Myocardial infarction (fatal & non fatal) 0.95 [0.76; 1.18] Acute coronary syndrome (MI ou unstable angina) 0.97 [0.82; 1.15] | | ACES, 2005 | Azithromycin vs placebo | | | all cause death 1.07 [0.85; 1.34] Myocardial infarction (fatal & non fatal) 1.04 [0.82; 1.31] Acute coronary syndrome (MI ou unstable angina) 1.01 [0.83; 1.22] | | STAMINA (Azithromycin), 2002 | Azithromycin vs placebo | | | all cause death 0.96 [0.29; 3.24] Acute coronary syndrome (MI ou unstable angina) 0.72 [0.45; 1.14] | | AZACS, 2003 | Azithromycin vs placebo | | | all cause death 1.07 [0.86; 1.32] Myocardial infarction (fatal & non fatal) 0.78 [0.42; 1.46] |
| Trial | Treatments | Patients | Method |
|---|
| Gupta et al, 1997 | Azithromycin 500 mg/d for 3 d (28 received 1 course, 12 received 2 courses 3 mo apart) (n=43) vs. placebo (n=41) | Male patients at least 6 mo from documented MI and with titers to Chlamydia pneumoniae >=1:64 | double blind Parallel groups Sample size: 43/41 Primary endpoint: not defined FU duration: 18mo | | ACADEMIC, 1999 | Azithromycin 500 mg/d for 3 d then 500 mg/wk for 3 mo (n=150) vs. placebo (n=152) | Patients with CAD and C pneumoniae titers of >=1:16. Patients were at least 5 d from an MI | double blind Parallel groups Sample size: 150/152 Primary endpoint: CV death, MI, stroke, unstable angina, revascularization FU duration: 2y | | WIZARD, 2003 | Azithromycin 600 mg/d for 3 d then 1/wk for 11 wk (n=3879) vs. placebo (n=3868) | Patients with a history of MI of more than 6 weeks before and with C pneumoniae titers of >=1:16 | double blind Parallel groups Sample size: 3879/3868 Primary endpoint: coronary events FU duration: 14mo | | ACES, 2005 | Azithromycin 600 mg/wk for 1 y (n=2004) vs. placebo (n=2008) | Patients with stable CAD | double blind Parallel groups Sample size: 2004/2008 Primary endpoint: coronary events FU duration: 4y | | STAMINA (Azithromycin), 2002 | Azithromycin 500 mg/d for 3 d plus omeprazole 20 mg 2/d for 1 wk plus metronidazole 400 mg 2/d for 1 wk (n=111) vs. placebo (n=107) | Patients with ACS | double blind Parallel groups Sample size: 111/107 Primary endpoint: not defined FU duration: 1y | | AZACS, 2003 | Azithromycin 500 mg on day 1 followed by 250 mg/d for 4d (n=2004) vs. placebo (n=2008) | Patients with ACS | double blind Parallel groups Sample size: 2004/2008 Primary endpoint: death, MI, revascularization FU duration: 6mo |
|
